x
Filter:
Filters applied
- dnMBC
Publication Date
Please choose a date range between 2020 and 2021.
Author
- Azuero, Andres1
- Barrios, Carlos Henrique1
- Bedin, Sabrina Richter1
- Burkard, Mark E1
- Conte, Benedetta1
- Daily, Karen1
- Douglas, Emily1
- Fregatti, Piero1
- Garrett-Mayer, Elizabeth1
- Gilbert, Aidan1
- Haji, Farnaz1
- Hurvitz, Sara A1
- Kenzik, Kelly1
- Lambertini, Matteo1
- Li, Xiaoxian1
- Meersman, Stephen1
- Meisel, Jane1
- Mullangi, Samyukta1
- O'Regan, Ruth1
- Prat, Aleix1
- Razeti, Maria Grazia1
- Reinert, Tomás1
- Rocque, Gabrielle1
- Romitti, Paul A1
- Rosa, Mahira Lopes1
Keyword
- Stage IV2
- AKT inhibitor1
- androgen receptor inhibitor1
- antibody-drug conjugate1
- BRCA1
- breast cancer in young women1
- Breast neoplasm1
- Breast neoplasms1
- Cancer staging1
- Complete response (CR)1
- De novo1
- Durable response1
- HER2-positive breast cancer1
- Hormone receptor-positive HER2-negative breast cancer1
- Incidence1
- Metastasis1
- Oligometastases1
- PARP inhibitor1
- PD-L11
- Positron emission tomography1
- Survival1
- Survivorship1
- Treatment practice patterns1
- Treatment sequence1
- Triple-negative breast cancer1
dnMBC
7 Results
- Research Article
Genomic Characterization of De Novo Metastatic Breast Cancer
Clinical Breast CancerVol. 22Issue 2p98–102Published online: November 26, 2021- Samyukta Mullangi
- Neil Vasan
Cited in Scopus: 0De novo metastatic breast cancer (dnMBC) represents a minority of MBC cases, and as such, its genomics are poorly understood. Characterizing the genomics of dnMBC represents an opportunity to delineate metastatic drivers in the absence of treatment selection. In this review, we first summarize the literature of the genomics of MBC which showed that MBCs have greater mutational burden than early stage, treatment naïve breast cancers. We then turn to recent studies that have sought to focus on dnMBC. - VSI dnMBC
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence
Clinical Breast CancerVol. 22Issue 1p78–87Published online: October 8, 2021- Benedetta Conte
- Davide Soldato
- Maria Grazia Razeti
- Piero Fregatti
- Evandro de Azambuja
- Francesco Schettini
- and others
Cited in Scopus: 3Women with metastatic breast cancer remains a heterogeneous group of patients with different prognostic outcomes and therapeutic needs. Young women with de novo metastatic breast cancer (dnMBC) represent a peculiar population with respect to tumor biology, prognosis, clinical management and survivorship issues. Overall, these patients are able to attain long-term survival with a proper management of both primary tumor and distant metastases. On the other hand, they are also at higher risk of experiencing a deterioration in their quality of life (QoL) due to primary cancer-related side effects. - Research Article
Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies
Clinical Breast CancerVol. 21Issue 6p509–520Published online: September 16, 2021- Elizabeth Sakach
- Ruth O'Regan
- Jane Meisel
- Xiaoxian Li
Cited in Scopus: 5Triple negative breast cancer (TNBC) represents 15% to 20% of all primary breast cancers and is the most aggressive subtype of breast cancer. There has been rapid progress in targeted therapy and biomarker development to identify the optimal treatments for TNBC. To update recent developments, this article comprehensively reviews molecular classification and biomarkers of TNBC and targeted therapy developments in immunotherapy, PARP and AKT pathway inhibitors, antibody-drug conjugates and androgen receptor blockade. - Original Study
Can Women With HER2-Positive Metastatic Breast Cancer Be Cured?
Clinical Breast CancerVol. 21Issue 6p526–531Published online: July 3, 2021- Farnaz Haji
- Sara A. Hurvitz
Cited in Scopus: 1Breast cancer that is characterized by amplification or over expression of human epidermal growth factor receptor 2 (HER2) accounts for 15% to 20% of all forms of the disease. Although HER2 amplification has been associated with aggressive disease behavior and poor prognosis, the development and availability of a number of HER2-targeted agents has led to improved outcomes for patients with HER2-positive metastatic breast cancer, with data suggesting that overall survival has substantially improved in the past 2 decades. - Research Article
Perspectives on the Systemic Staging in Newly Diagnosed Breast Cancer
Clinical Breast CancerVol. 21Issue 4p309–316Published online: March 27, 2021- Tomás Reinert
- Alessandra Borba Anton de Souza
- Mahira Lopes Rosa
- Sabrina Richter Bedin
- Carlos Henrique Barrios
Cited in Scopus: 0Breast cancer is a complex disease, and accurate systemic staging is an essential aspect of the evaluation of a patient with newly diagnosed breast cancer. Considering that the chance of having metastatic disease at breast cancer diagnosis is different in each patient and depends on a variety of anatomic and biologic factors, it is crucial to understand that some populations may benefit from more intensive staging because their pretest probability of metastatic disease is higher than that of the average patient. - Research Article
Epidemiology of De Novo Metastatic Breast Cancer
Clinical Breast CancerVol. 21Issue 4p302–308Published online: January 31, 2021- Karen Daily
- Emily Douglas
- Paul A. Romitti
- Alexandra Thomas
Cited in Scopus: 10Most cases of metastatic breast cancer (MBC) arise as a recurrence of a previously treated early breast cancer. Distinct from recurrent MBC is de novo MBC (dnMBC), which describes patients who present with distant sites of disease at initial diagnosis and is reviewed here. dnMBC represents approximately 3% to 6% of new breast cancer diagnoses in high-income countries. This incidence has not declined despite decades of widespread use of population-based mammography screening. Overrepresentation of both biologically aggressive tumors and patients negatively impacted by social determinants of health are characteristics of dnMBC. - De novo MBC (dnMBC)
Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer
Clinical Breast CancerVol. 21Issue 4p292–301Published online: November 17, 2020- Aidan Gilbert
- Courtney Williams
- Andres Azuero
- Mark E. Burkard
- Kelly Kenzik
- Elizabeth Garrett-Mayer
- and others
Cited in Scopus: 2Micro-Abstract De novo stage IV metastatic breast cancer (MBC) and early stage breast cancer that progresses to metastatic disease (recurrent MBC) are considered the same when determining guideline-based care, but differences in treatment patterns exist. This study used a novel visualization approach to identify differences and similarities in treatment between de novo and recurrent MBC.